标题
ErbB2 signaling at the crossing between heart failure and cancer
作者
关键词
Neuregulin-1, ErbB2 signaling, Cardiotoxicity
出版物
BASIC RESEARCH IN CARDIOLOGY
Volume 111, Issue 6, Pages -
出版商
Springer Nature
发表日期
2016-09-05
DOI
10.1007/s00395-016-0576-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular risk
- (2016) Leni Vandekerckhove et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Neuregulin-1 Administration Protocols Sufficient for Stimulating Cardiac Regeneration in Young Mice Do Not Induce Somatic, Organ, or Neoplastic Growth
- (2016) Balakrishnan Ganapathy et al. PLoS One
- Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS–p110 crosstalk
- (2016) Rastislav Tamaskovic et al. Nature Communications
- Mechanisms of lapatinib resistance in HER2-driven breast cancer
- (2015) Valentina D’Amato et al. CANCER TREATMENT REVIEWS
- Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension
- (2015) Pedro Mendes-Ferreira et al. CARDIOVASCULAR RESEARCH
- Cardio-Oncology
- (2015) Andrew M. Bellinger et al. CIRCULATION
- Medicine: Eyes on the target
- (2015) Michael Eisenstein NATURE
- ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation
- (2015) Gabriele D’Uva et al. NATURE CELL BIOLOGY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neuregulin 1 Improves Glucose Tolerance in db/db Mice
- (2015) Gaël Ennequin et al. PLoS One
- Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window
- (2015) Brian D. Polizzotti et al. Science Translational Medicine
- Signalling between microvascular endothelium and cardiomyocytes through neuregulin
- (2014) Emily M. Parodi et al. CARDIOVASCULAR RESEARCH
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Anti‐Remodeling and Anti‐Fibrotic Effects of the Neuregulin‐1β Glial Growth Factor 2 in a Large Animal Model of Heart Failure
- (2014) Cristi L. Galindo et al. Journal of the American Heart Association
- An Engineered Bivalent Neuregulin Protects Against Doxorubicin-Induced Cardiotoxicity With Reduced Proneoplastic Potential
- (2013) Steven M. Jay et al. CIRCULATION
- Cardiotoxicity of novel HER2-targeted therapies
- (2013) Mehmet A.N. Sendur et al. CURRENT MEDICAL RESEARCH AND OPINION
- Therapeutic potential of neuregulin-1 in cardiovascular disease
- (2013) Pedro Mendes-Ferreira et al. DRUG DISCOVERY TODAY
- Mechanisms of cardiotoxicity associated with ErbB2 inhibitors
- (2012) Carmine Fedele et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- Neuregulin in Cardiovascular Development and Disease
- (2012) Oghenerukevwe Odiete et al. CIRCULATION RESEARCH
- Therapeutic effects of neuregulin-1 gene transduction in rats with myocardial infarction
- (2012) Jian Xiao et al. CORONARY ARTERY DISEASE
- Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2012) Javier Cortés et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies
- (2012) Sara A. Hurvitz et al. Therapeutic Advances in Medical Oncology
- Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
- (2011) D. Lenihan et al. ANNALS OF ONCOLOGY
- Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats
- (2011) Bingong Li et al. Cardiovascular Diabetology
- Endothelium-Derived Neuregulin Protects the Heart Against Ischemic Injury
- (2011) Nadia Hedhli et al. CIRCULATION
- Engineered Bivalent Ligands to Bias ErbB Receptor-mediated Signaling and Phenotypes
- (2011) Steven M. Jay et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy
- (2010) Katrien Lemmens et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin
- (2010) Xinghua Gu et al. CARDIOVASCULAR RESEARCH
- The Vulnerability of the Heart As a Pluricellular Paracrine Organ
- (2010) Gilles W. De Keulenaer et al. CIRCULATION RESEARCH
- Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses
- (2010) Andrew Jabbour et al. EUROPEAN JOURNAL OF HEART FAILURE
- Expression, localization, and regulation of the neuregulin receptor ErbB3 in mouse heart
- (2010) Genís Campreciós et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II, Randomized, Double-Blind, Multicenter, Based on Standard Therapy, Placebo-Controlled Study of the Efficacy and Safety of Recombinant Human Neuregulin-1 in Patients With Chronic Heart Failure
- (2010) Runlin Gao et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins
- (2009) Yun Bian et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury
- (2009) Kevin Bersell et al. CELL
- Preventive Effects of Heregulin-β 1 on Macrophage Foam Cell Formation and Atherosclerosis
- (2009) Gang Xu et al. CIRCULATION RESEARCH
- Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
- (2009) Edith A. Perez et al. MAYO CLINIC PROCEEDINGS
- Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
- (2009) B. Schoeberl et al. Science Signaling
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started